Guggenheim Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $35
Benzinga Newsdesk 9 months ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Brad Canino initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $35.
Guggenheim analyst Brad Canino initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $35.